ABSTRACT
A 63-year old with an 8-month history of backache had a leiomyosarcoma of the inferior vena cava. Although inoperable, she benefitted from cobalt therapy. A review of the literature suggests an evolving clinical picture which will facilitate earlier diagnosis, and perhaps allow resection.
Subject(s)
Cobalt/therapeutic use , Female , Follow-Up Studies , Humans , Leiomyosarcoma/diagnosis , Middle Aged , Palliative Care , Vascular Neoplasms/diagnosis , Vena Cava, InferiorABSTRACT
Two patients were successfully treated for sternal tuberculous osteomyelitis with quandruple anti-tuberculous chemotherapy and surgical exploration. The diagnosis was confirmed in one. In the other the clinical presentation was characteristic of a tuberculous aetiology.
Subject(s)
Adult , Antitubercular Agents/therapeutic use , Child , Combined Modality Therapy , Disease-Free Survival , Female , Humans , Male , Osteomyelitis/diagnosis , Sternum , Surgical Procedures, Operative , Tuberculosis, Osteoarticular/diagnosisABSTRACT
The main problems of heart valve replacement in Sri Lanka are the cost of prosthetic valves and anticoagulant related complications. The use of human donor heart valves (homografts; allogeneic heart valves [AHV]) will alleviate these shortcomings. Recipients of AHV do not require anticoagulant therapy. Moreover, cryopreservation of AHV offers the opportunity for the storage of valves for an extended length of time with the preservation of valve integrity which is essential for their function after implantation. A donor valve bank can potentially provide diameter matched valves for recipients. Current research suggests that the adverse immunological reactions initiated by AHV cause tissue degeneration in a proportion of these implants. However, the grafts may be improved before implantation during the disinfection and storage of the valves. In this essay an overview on the advantages of using AHV, current concepts of valve banking, recent advances in the understanding of AHV immunogenicity, emerging techniques for immunomodulation of AHV and the possibility of setting up a donor heart valve bank in Sri Lanka are discussed.